Physician profile
Sameera Syed
NPI 1073020962
$642.81
in general payments reported to CMS, 2019-2025
17 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.73 · 2020: $107 · 2021: $70.28 · 2022: $104 · 2023: $44.41 · 2024: $74.68 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $331.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $122.91 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $89.84 | 2020-2021 | |
| Corcept Therapeutics | $49.78 | 2024-2025 | Korlym |
| Biohaven Pharmaceutical Holding Company Ltd. | $47.90 | 2022 | |
| Exact Sciences Corporation | $45.20 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $43.47 | 2022-2024 | Rexulti |
| Glaxosmithkline, LLC. | $38.57 | 2020-2022 | |
| Novo Nordisk INC | $36.46 | 2025 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $31.62 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbvie INC. | $30.16 | 2023-2025 | Qulipta |
| Phathom Pharmaceuticals, INC. | $18.62 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $16.14 | 2025 | Gemtesa |
| Amgen INC. | $14.99 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.98 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.75 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13.79 | 2023 | |
| Esperion Therapeutics, INC. | $13.63 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameera Syed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.